Ernexa Therapeutics (ERNAW) Operating Expenses (2010 - 2026)

Ernexa Therapeutics has reported Operating Expenses for 17 years, with the latest figure at $5.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 104.76% year-over-year to $5.6 million; the trailing twelve-month figure through Mar 2026 stood at $12.2 million (down 7.16% YoY), and the FY2025 full-year result was $9.3 million, down 42.33% from the prior year.
• Operating Expenses for Q1 2026 stood at $5.6 million, up from $2.1 million in the prior quarter.
• The five-year high for Operating Expenses was $13.9 million in Q2 2022, with the low at $2.0 million in Q3 2025.
• Historically, Operating Expenses has averaged $5.0 million across 5 years, with a median of $4.9 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Expenses sank 90.38% — and 2026, when it surged 104.76%.
• Ernexa Therapeutics' Operating Expenses stood at $4.7 million in 2022, then grew by 20.67% to $5.7 million in 2023, then sank by 52.8% to $2.7 million in 2024, then slipped by 22.39% to $2.1 million in 2025, then soared by 166.95% to $5.6 million in 2026.
• The last three Operating Expenses figures came in at $5.6 million (Q1 2026), $2.1 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.